12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xgeva: Additional Phase III data

A post hoc subgroup analysis of 846 men with CRPC and a prostate specific antigen (PSA) doubling time of <6 months in the double-blind, international Phase III 20050147 trial showed that 120 mg subcutaneous Xgeva every 4 weeks significantly improved median time to first occurrence of bone metastasis or death from any cause, the primary endpoint, by 7.2 months vs. placebo (25.9 vs. 18.7 months, p=0.0064). Xgeva also significantly improved the endpoint in men with a PSA doubling time of <=10 months vs. placebo (28.4 vs. 22.4 months, p=0.042). Amgen said previous studies have shown...

Read the full 452 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >